Current Report Filing (8-k)
June 17 2022 - 6:01AM
Edgar (US Regulatory)
0001725430
false
0001725430
2022-06-16
2022-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): June 16, 2022
GBS
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39825 |
|
82-1512711 |
(State
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
employer identification no.) |
420
Lexington Ave, Suite 300 |
New
York, NY 10170 |
(Address
of principal executive offices, including zip code) |
Registrant’s
telephone number, including area code: (646) 828-8258
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
GBS |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. |
Entry
into a Material Definitive Agreement. |
On
June 16, 2022, GBS Inc. (the “Company”) executed an agreement with Intelligent Fingerprinting
Limited (“IFP”), providing the Company with the exclusive right until December 31, 2022 (subject to IFP’s right to
terminate the agreement early after August 31, 2022), to evaluate and negotiate a transaction to acquire IFP or its assets (or a similar
transaction). In consideration for this exclusivity, on June 16, 2022, the Company entered
into a Bridge Facility Agreement with IFP (the “Bridge Facility Agreement”) through which the Company will
provide IFP with an unsecured term loan facility in the amount of $500,000 (USD) (the “Loan”), which amount is payable
on the earliest of the consummation of an acquisition, 30 days following the termination of exclusivity under the exclusivity agreement,
an event of default under the Bridge Facility Agreement, or December 31, 2022. The Loan contains customary representations and warranties
by IFP and bears interest at two percent per annum (or four percent per annum in the event the Loan is not repaid in full when due) above
the Sterling Barclays Bank Base Rate from time to time.
Completion
of the proposed transaction contemplated by the Exclusivity Agreement is subject to the negotiation of a definitive agreement providing
for the transaction and satisfaction of any conditions negotiated therein. Accordingly, there can be no assurance that a definitive agreement
will be entered into or that the proposed transaction will be consummated, or if a transaction is consummated, as to its terms, structure,
or timing.
Item
7.01. |
Regulation
FD Disclosure. |
On
June 16, 2022, the Company issued a press release announcing the Exclusivity Agreement, the
Bridge Facility Agreement and the Loan. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference.
The
information in this Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the
Securities Act of 1933 or the Exchange Act, except as otherwise stated in such filing.
Forward-Looking
Statements:
Some
of the statements in this Current Report on Form 8-K are forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this Current Report on Form 8-K include, without limitation, the
Company’s ability to consummate the proposed transaction described in this Current Report on Form
8-K, develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure
regulatory approvals, among others. Although the Company believes that the expectations reflected
in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from
the results expressed or implied by such forward-looking statements. The Company has attempted to
identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “projects,” “intends,” “potential,” “may,”
“could,” “might,” “will,” “should,” “approximately” or other words that convey
uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve
known and unknown risks, uncertainties, and other factors, included in the Company’s public
filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K
speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this Current Report
on Form 8-K to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Item
9.01. |
Financial
Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 16, 2022 |
|
|
|
GBS INC. |
|
|
|
|
By:
|
/s/
Spiro Sakiris |
|
Name:
|
Spiro
Sakiris |
|
Title: |
Chief
Financial Officer |
GBS (NASDAQ:GBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
GBS (NASDAQ:GBS)
Historical Stock Chart
From Jul 2023 to Jul 2024